AR and prostate cancer: observed that TXNDC5 was upregulated in prostate cancer cells after prolonged androgen deprivation therapy (ADT) due to ADT-induced hypoxia upregulating TXNDC5 expression through androgen receptor (AR) protein signaling, thereby enhancing their interaction, stability and transcriptional activity.